-
1
-
-
0000078117
-
Molecular biology of cancer: Invasion and metastases
-
Devita VT, Hellman, S, Rosenberg SA (Eds). Lippincott- Raven, PA, USA
-
Fidler IJ. Molecular biology of cancer: invasion and metastases. In: Cancer Principles and Practice of Oncology. Devita VT, Hellman, S, Rosenberg SA (Eds). Lippincott- Raven, PA, USA, 135-152 (1997).
-
(1997)
Cancer Principles and Practice of Oncology
, pp. 135-152
-
-
Fidler, I.J.1
-
2
-
-
0026008680
-
Metastatic breast cancer: Length and quality of life
-
Norton L. Metastatic breast cancer: length and quality of life. N. Engl. J. Med. 325, 1370-1371 (1991).
-
(1991)
N. Engl. J. Med.
, vol.325
, pp. 1370-1371
-
-
Norton, L.1
-
3
-
-
41649102043
-
The cancer biomarker problem
-
Sawyers CL. The cancer biomarker problem. Nature 452(7187), 548-552 (2008).
-
(2008)
Nature
, vol.452
, Issue.7187
, pp. 548-552
-
-
Sawyers, C.L.1
-
4
-
-
28544446695
-
Biomarkers in cancer staging, prognosis and treatment selection
-
Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5(11), 845-856 (2005).
-
(2005)
Nat. Rev. Cancer
, vol.5
, Issue.11
, pp. 845-856
-
-
Ludwig, J.A.1
Weinstein, J.N.2
-
5
-
-
0036674501
-
Dissemination and growth of cancer cells in metastatic sites
-
Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563-572 (2002).
-
(2002)
Nat. Rev. Cancer
, vol.2
, pp. 563-572
-
-
Chambers, A.F.1
Groom, A.C.2
MacDonald, I.C.3
-
6
-
-
0036675220
-
Metastases to bone: Causes, consequences and therapeutic opportunities
-
Mundy GR. Metastases to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584-593 (2002).
-
(2002)
Nat. Rev. Cancer
, vol.2
, pp. 584-593
-
-
Mundy, G.R.1
-
7
-
-
0018864610
-
The pathogenesis of cancer metastasis
-
Poste G and Fidler IJ. The pathogenesis of cancer metastasis. Nature 283, 139-146 (1980).
-
(1980)
Nature
, vol.283
, pp. 139-146
-
-
Poste, G.1
Fidler, I.J.2
-
9
-
-
0034680102
-
Molecular portraits of human breast tumors
-
Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumors. Nature 406, 747-752 (2000).
-
(2000)
Nature
, vol.406
, pp. 747-752
-
-
Perou, C.M.1
Sorlie, T.2
Eisen, M.B.3
-
10
-
-
0035845511
-
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
-
Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
-
(2001)
Proc. Natl Acad. Sci. USA
, vol.98
, pp. 10869-10874
-
-
Sorlie, T.1
Perou, C.M.2
Tibshirani, R.3
-
11
-
-
66549111590
-
Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up
-
Cardoso F, Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20(Suppl. 4), 15-18 (2009).
-
(2009)
Ann. Oncol.
, vol.20
, Issue.SUPPL. 4
, pp. 15-18
-
-
Cardoso, F.1
Castiglione, M.2
-
12
-
-
63549116437
-
Survival among women with triple receptor-negative breast cancer and brain metastases
-
Dawood S, Broglio K, Esteva FJ et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann. Oncol. 20(4), 621-627 (2009).
-
(2009)
Ann. Oncol.
, vol.20
, Issue.4
, pp. 621-627
-
-
Dawood, S.1
Broglio, K.2
Esteva, F.J.3
-
13
-
-
70449698237
-
Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases
-
Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J. Clin. Oncol. 27(31), 5278-5286 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.31
, pp. 5278-5286
-
-
Leyland-Jones, B.1
-
14
-
-
23144461051
-
Genes that mediate breast cancer metastasis to lung
-
Minn AJ, Gupta GP, Siegel PM et al. Genes that mediate breast cancer metastasis to lung. Nature 436(7050), 518-524 (2005).
-
(2005)
Nature
, vol.436
, Issue.7050
, pp. 518-524
-
-
Minn, A.J.1
Gupta, G.P.2
Siegel, P.M.3
-
15
-
-
58149340543
-
Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer
-
Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin. Cancer Res. 4(24), 8019-8026 (2008).
-
(2008)
Clin. Cancer Res.
, vol.4
, Issue.24
, pp. 8019-8026
-
-
Dowsett, M.1
Dunbier, A.K.2
-
16
-
-
19944422061
-
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
-
Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004).
-
(2004)
N. Engl. J. Med.
, vol.351
, Issue.27
, pp. 2817-2826
-
-
Paik, S.1
Shak, S.2
Tang, G.3
-
17
-
-
0037137519
-
A gene-expression signature as a predictor of survival in breast cancer
-
van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002).
-
(2002)
N. Engl. J. Med.
, vol.347
, Issue.25
, pp. 1999-2009
-
-
Van De Vijver, M.J.1
He, Y.D.2
Van'T Veer, L.J.3
-
19
-
-
58149232649
-
Unraveling the biologic and clinical complexities of HER2
-
Park JW, Neve RM, Szollosi J, Benz CC. Unraveling the biologic and clinical complexities of HER2. Clin. Breast Cancer 8(5), 392-401 (2008).
-
(2008)
Clin. Breast Cancer
, vol.8
, Issue.5
, pp. 392-401
-
-
Park, J.W.1
Neve, R.M.2
Szollosi, J.3
Benz, C.C.4
-
20
-
-
73349085919
-
Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer
-
Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 27(34), 5838-5847 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.34
, pp. 5838-5847
-
-
Spector, N.L.1
Blackwell, K.L.2
-
21
-
-
50849123421
-
HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target
-
Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 19(9), 1523-1529 (2008).
-
(2008)
Ann. Oncol.
, vol.19
, Issue.9
, pp. 1523-1529
-
-
Gravalos, C.1
Jimeno, A.2
-
22
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
-
(2001)
N. Engl. J. Med.
, vol.344
, Issue.11
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
23
-
-
73949090721
-
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review
-
Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J. Clin. Oncol. 28(1), 92-98 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.1
, pp. 92-98
-
-
Dawood, S.1
Broglio, K.2
Buzdar, A.U.3
Hortobagyi, G.N.4
Giordano, S.H.5
-
24
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
-
(2005)
N. Engl. J. Med.
, vol.353
, Issue.16
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
-
25
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
Piccart-Gebhart MJ, Procter M, Leyland- Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005).
-
(2005)
N. Engl. J. Med.
, vol.353
, Issue.16
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland- Jones, B.3
-
26
-
-
70350204423
-
Efficacy results from the ToGA trial: A Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)
-
Abstract LBA4509
-
Van Cutsem E, KangY , Chung H et al. Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J. Clin. Oncol. 27(Suppl.), 18s (2009) (Abstract LBA4509).
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.SUPPL.
-
-
Van Cutsem, E.1
Kangy Chung, H.2
-
27
-
-
11244258222
-
Epidermal growth factor receptor inhibition strategies in oncology
-
Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr. Relat. Cancer 11 (4), 689-708 (2004).
-
(2004)
Endocr. Relat. Cancer
, vol.11
, Issue.4
, pp. 689-708
-
-
Harari, P.M.1
-
29
-
-
0030980781
-
Over expression of the epidermal growth factor receptor and its ligand transforming growth a is frequent in resectable non-small cell lung cancer but does not predict tumor progression
-
Rusch VD, Klimstra E, Venkatraman P et al. Over expression of the epidermal growth factor receptor and its ligand transforming growth a is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 3, 515-522 (1997).
-
(1997)
Clin. Cancer Res.
, vol.3
, pp. 515-522
-
-
Rusch, V.D.1
Klimstra, E.2
Venkatraman, P.3
-
30
-
-
0142119289
-
Epidermal growth factor receptor in non-small cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis
-
Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21, 3798-3807 (2003).
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 3798-3807
-
-
Hirsch, F.R.1
Varella-Garcia, M.2
Bunn Jr., P.A.3
-
31
-
-
3042663513
-
Cetuximab in advanced non-small cell lung cancer
-
Govindan R. Cetuximab in advanced non-small cell lung cancer. Clin. Cancer Res. 10, 4241s-4244s (2004).
-
(2004)
Clin. Cancer Res.
, vol.10
-
-
Govindan, R.1
-
32
-
-
65349116059
-
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised Phase III trial
-
Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised Phase III trial. Lancet 373(9674), 1525-1531 (2009).
-
(2009)
Lancet
, vol.373
, Issue.9674
, pp. 1525-1531
-
-
Pirker, R.1
Pereira, J.R.2
Szczesna, A.3
-
33
-
-
39849111354
-
A randomized multicenter Phase III study of cetuximab (Erbitux) in combination with taxane/carboplatin alone as first-line treatment for patients with advanced/ metastatic non-small lung cancer (NSCLC)
-
Lynch TJ, Patel T, Dreisbach L et al. A randomized multicenter Phase III study of cetuximab (Erbitux) in combination with taxane/carboplatin alone as first-line treatment for patients with advanced/ metastatic non-small lung cancer (NSCLC). J. Thorac. Oncol. 2, S340-S341 (2007).
-
(2007)
J. Thorac. Oncol.
, vol.2
-
-
Lynch, T.J.1
Patel, T.2
Dreisbach, L.3
-
34
-
-
74949133978
-
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer
-
Azzoli CG, Baker S Jr, Temin S et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol. 27(36), 6251-6266 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.36
, pp. 6251-6266
-
-
Azzoli, C.G.1
Baker Jr., S.2
Temin, S.3
-
35
-
-
4444344330
-
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
-
Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306-13311 (2004).
-
(2004)
Proc. Natl Acad. Sci. USA
, vol.101
, pp. 13306-13311
-
-
Pao, W.1
Miller, V.2
Zakowski, M.3
-
36
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib
-
Lynch TJ, Bell DW Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
-
(2004)
N. Engl. J. Med.
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
-
37
-
-
70349376330
-
Molecular predictive and prognostic markers in non-small-cell lung cancer
-
Coate LE, John T, Tsao MS, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol. 10(10), 1001-1010 (2009).
-
(2009)
Lancet Oncol.
, vol.10
, Issue.10
, pp. 1001-1010
-
-
Coate, L.E.1
John, T.2
Tsao, M.S.3
Shepherd, F.A.4
-
38
-
-
24944440830
-
TRIBUTE: A Phase III trial of erlotinib hydrochloride (OSI) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
-
Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23, 5892-5899 (2005).
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 5892-5899
-
-
Herbst, R.S.1
Prager, D.2
Hermann, R.3
-
39
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
-
(2009)
N. Engl. J. Med.
, vol.361
, Issue.10
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
-
40
-
-
70349388721
-
Understanding prognostic gene expression signatures in lung cancer
-
Zhu CQ, Pintilie M, John T et al. Understanding prognostic gene expression signatures in lung cancer. Clin. Lung Cancer 10(5), 331-340 (2009).
-
(2009)
Clin. Lung Cancer
, vol.10
, Issue.5
, pp. 331-340
-
-
Zhu, C.Q.1
Pintilie, M.2
John, T.3
-
41
-
-
61549108338
-
EGFR T790M mutation: A double role in lung cancer cell survival?
-
Suda K, Onozato R, Yatabe Y, Mitsudomi T. EGFR T790M mutation: a double role in lung cancer cell survival? J. Thorac. Oncol. 4(1), 1-4 (2009).
-
(2009)
J. Thorac. Oncol.
, vol.4
, Issue.1
, pp. 1-4
-
-
Suda, K.1
Onozato, R.2
Yatabe, Y.3
Mitsudomi, T.4
-
42
-
-
2142641698
-
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
-
Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22(7), 1201-1208 (2004).
-
(2004)
J. Clin. Oncol.
, vol.22
, Issue.7
, pp. 1201-1208
-
-
Saltz, L.B.1
Meropol, N.J.2
Loehrer Sr., P.J.3
Needle, M.N.4
Kopit, J.5
Mayer, R.J.6
-
43
-
-
20144381957
-
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
-
Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23(9), 1803-1810 (2005).
-
(2005)
J. Clin. Oncol.
, vol.23
, Issue.9
, pp. 1803-1810
-
-
Chung, K.Y.1
Shia, J.2
Kemeny, N.E.3
-
44
-
-
17844362179
-
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study
-
Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6(5), 279-286 (2005).
-
(2005)
Lancet Oncol.
, vol.6
, Issue.5
, pp. 279-286
-
-
Moroni, M.1
Veronese, S.2
Benvenuti, S.3
-
45
-
-
19944422060
-
Somatic mutations of EGFR in colorectal cancers and glioblastomas
-
Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med. 351(27), 2883 (2004).
-
(2004)
N. Engl. J. Med.
, vol.351
, Issue.27
, pp. 2883
-
-
Barber, T.D.1
Vogelstein, B.2
Kinzler, K.W.3
Velculescu, V.E.4
-
46
-
-
35148842402
-
Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor (EGFr) levels: An updated analysis
-
Abstract 4081
-
Mitchell EP , Hecht JR, Baranda J et al. Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor (EGFr) levels: an updated analysis. J. Clin. Oncol. 25(18 Suppl.) (2007) (Abstract 4081).
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.18 SUPPL.
-
-
Mitchell, E.P.1
Hecht, J.R.2
Baranda, J.3
-
47
-
-
70349939382
-
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer
-
Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl Cancer Inst. 101(19), 1308-1324 (2009).
-
(2009)
J. Natl Cancer Inst.
, vol.101
, Issue.19
, pp. 1308-1324
-
-
Siena, S.1
Sartore-Bianchi, A.2
Di Nicolantonio, F.3
Balfour, J.4
Bardelli, A.5
-
48
-
-
0024376173
-
Ras oncogenes in human cancer: A review
-
Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 49(17), 4682-4689 (1989).
-
(1989)
Cancer Res.
, vol.49
, Issue.17
, pp. 4682-4689
-
-
Bos, J.L.1
-
49
-
-
33748063941
-
Roles of the RAF/MEK/ERK and PI3k/PTEN/AKT pathways in malignant transformation and drug resistance
-
McCubrey JA, Steelman LS, Abrams SL et al. Roles of the RAF/MEK/ERK and PI3k/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 46(1), 249-279 (2006).
-
(2006)
Adv. Enzyme Regul.
, vol.46
, Issue.1
, pp. 249-279
-
-
McCubrey, J.A.1
Steelman, L.S.2
Abrams, S.L.3
-
50
-
-
0025312728
-
A genetic model for colorectal tumorigenesis
-
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61(5), 759-767 (1990).
-
(1990)
Cell
, vol.61
, Issue.5
, pp. 759-767
-
-
Fearon, E.R.1
Vogelstein, B.2
-
51
-
-
42149083899
-
Mutations in the RAS-MAPK PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers
-
Barault L, Veyrie N, Jooste V et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int. J. Cancer 122(10), 2255-2259 (2008).
-
(2008)
Int. J. Cancer
, vol.122
, Issue.10
, pp. 2255-2259
-
-
Barault, L.1
Veyrie, N.2
Jooste, V.3
-
52
-
-
0032855959
-
K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: A combined analysis of 881 cases
-
Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 20(8), 1507-1510 (1999).
-
(1999)
Carcinogenesis
, vol.20
, Issue.8
, pp. 1507-1510
-
-
Huncharek, M.1
Muscat, J.2
Geschwind, J.F.3
-
53
-
-
42649145667
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 1626-1634
-
-
Amado, R.G.1
Wolf, M.2
Peeters, M.3
-
54
-
-
51649120733
-
KRAS status and efficacy of first-line treatment of patients with metastatic colorectal (metastatic CRC) with FOLFOX with or without cetuximab: The OPUS experience
-
Abstract 4000
-
Bokemeyer C, Bondarenko I, Hartmann JT et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal (metastatic CRC) with FOLFOX with or without cetuximab: the OPUS experience. J. Clin. Oncol. 26(Suppl.), 178s (2008) (Abstract 4000).
-
(2008)
J. Clin. Oncol.
, vol.26
, Issue.SUPPL.
-
-
Bokemeyer, C.1
Bondarenko, I.2
Hartmann, J.T.3
-
55
-
-
54949085398
-
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
-
Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008)
-
(2008)
N. Engl. J. Med.
, vol.359
, pp. 1757-1765
-
-
Karapetis, C.S.1
Khambata-Ford, S.2
Jonker, D.J.3
-
56
-
-
49149109102
-
Randomized Phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)
-
Abstract LBA4011
-
Punt CJ, Tol J, Rodenburg CJ et al. Randomized Phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J. Clin. Oncol. 26(Suppl.), 180s (2008) (Abstract LBA4011).
-
(2008)
J. Clin. Oncol.
, vol.26
, Issue.SUPPL.
-
-
Punt, C.J.1
Tol, J.2
Rodenburg, C.J.3
-
57
-
-
51649120733
-
KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (metastatic CRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience
-
Abstract 2
-
Van Cutsem E, Lang I, D'haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (metastatic CRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J. Clin. Oncol. 26(Suppl.), 5s (2008) (Abstract 2).
-
(2008)
J. Clin. Oncol.
, vol.26
, Issue.SUPPL.
-
-
Van Cutsem, E.1
Lang, I.2
D'Haens, G.3
-
58
-
-
65349189958
-
American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
-
Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27(12), 2091-2096 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.12
, pp. 2091-2096
-
-
Allegra, C.J.1
Jessup, J.M.2
Somerfield, M.R.3
-
59
-
-
57449095367
-
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
-
Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26(35), 5705-5712 (2008).
-
(2008)
J. Clin. Oncol.
, vol.26
, Issue.35
, pp. 5705-5712
-
-
Di Nicolantonio, F.1
Martini, M.2
Molinari, F.3
-
60
-
-
67649652208
-
BRAF mutation in metastatic colorectal cancer
-
Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 361(1), 98-99 (2009).
-
(2009)
N. Engl. J. Med.
, vol.361
, Issue.1
, pp. 98-99
-
-
Tol, J.1
Nagtegaal, I.D.2
Punt, C.J.3
-
61
-
-
35348908314
-
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
-
Frattini M, Saletti P, Romagnani E et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer 97(8), 1139-1145 (2007).
-
(2007)
Br. J. Cancer
, vol.97
, Issue.8
, pp. 1139-1145
-
-
Frattini, M.1
Saletti, P.2
Romagnani, E.3
-
62
-
-
62449302407
-
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
-
Sartore-Bianchi A, Martini M, Molinari F et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69(5), 1851-1857 (2009).
-
(2009)
Cancer Res.
, vol.69
, Issue.5
, pp. 1851-1857
-
-
Sartore-Bianchi, A.1
Martini, M.2
Molinari, F.3
-
63
-
-
33751377398
-
The clinical significance of circulating tumor cells in the peripheral blood
-
Elshimali YI, Grody WW. The clinical significance of circulating tumor cells in the peripheral blood. Diagn. Mol. Pathol. 15(4), 187-194 (2006).
-
(2006)
Diagn. Mol. Pathol.
, vol.15
, Issue.4
, pp. 187-194
-
-
Elshimali, Y.I.1
Grody, W.W.2
-
64
-
-
0036595629
-
Epithelial-mesenchymal transitions in tumour progression
-
Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2(6), 442-454 (2002).
-
(2002)
Nat. Rev. Cancer
, vol.2
, Issue.6
, pp. 442-454
-
-
Thiery, J.P.1
-
65
-
-
34848826864
-
Epithelial - Mesenchymal and mesenchymal - Epithelial transitions in carcinoma progression
-
Hugo H, Ackland ML, Blick T et al. Epithelial - mesenchymal and mesenchymal - epithelial transitions in carcinoma progression. J. Cell Physiol. 213(2), 374-383 (2007).
-
(2007)
J. Cell Physiol.
, vol.213
, Issue.2
, pp. 374-383
-
-
Hugo, H.1
Ackland, M.L.2
Blick, T.3
-
66
-
-
75449084154
-
Circulating tumor cells: Evolving evidence and future challenges
-
Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ. Circulating tumor cells: evolving evidence and future challenges. Oncologist 14(11), 1070-1082 (2009).
-
(2009)
Oncologist
, vol.14
, Issue.11
, pp. 1070-1082
-
-
Dotan, E.1
Cohen, S.J.2
Alpaugh, K.R.3
Meropol, N.J.4
-
67
-
-
6044259206
-
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
-
Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10, 6897-6904 (2004).
-
(2004)
Clin. Cancer Res.
, vol.10
, pp. 6897-6904
-
-
Allard, W.J.1
Matera, J.2
Miller, M.C.3
-
68
-
-
4143094988
-
Circulating tumor cells predict progression free survival and overall survival in metastatic breast cancer
-
Cristofanilli M, Budd GT, Ellis M et al. Circulating tumor cells predict progression free survival and overall survival in metastatic breast cancer. N. Engl. J. Med. 351, 781-791 (2004).
-
(2004)
N. Engl. J. Med.
, vol.351
, pp. 781-791
-
-
Cristofanilli, M.1
Budd, G.T.2
Ellis, M.3
-
69
-
-
33947286218
-
Circulating tumor cells in metastatic breast cancer: Biologic staging beyond tumor burden
-
Cristofanilli M, Broglio KR, Guarneri V et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin. Breast Cancer 6, 471-479 (2007).
-
(2007)
Clin. Breast Cancer
, vol.6
, pp. 471-479
-
-
Cristofanilli, M.1
Broglio, K.R.2
Guarneri, V.3
-
70
-
-
33846814619
-
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival
-
Hayes DF, Cristofanilli M, Budd GT et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 12(14), 4218-4224 (2006).
-
(2006)
Clin. Cancer Res.
, vol.12
, Issue.14
, pp. 4218-4224
-
-
Hayes, D.F.1
Cristofanilli, M.2
Budd, G.T.3
-
71
-
-
33751272999
-
Circulating tumor cells versus imaging - Predicting overall survival in metastatic breast cancer
-
DOI 10.1158/1078-0432.CCR-05-1769
-
Budd GT, Cristofanilli M, Eillis MJ et al. Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12(21), 6403-6409 (2006). (Pubitemid 44799711)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.21
, pp. 6403-6409
-
-
Budd, G.T.1
Cristofanilli, M.2
Ellis, M.J.3
Stopeck, A.4
Borden, E.5
Miller, M.C.6
Matera, J.7
Repollet, M.8
Doyle, G.V.9
Terstappen, L.W.M.M.10
Hayes, D.F.11
-
72
-
-
55549115023
-
Circulating tumor cells in metastatic breast cancer: From prognostic stratification to modification of the staging system?
-
Dawood S, Broglio K, Valero V et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer 113(9), 2422-2430 (2008).
-
(2008)
Cancer
, vol.113
, Issue.9
, pp. 2422-2430
-
-
Dawood, S.1
Broglio, K.2
Valero, V.3
-
73
-
-
70449561613
-
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients
-
Pestrin M, Bessi S, Galardi F et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res. Treat. 118(3), 523-530 (2009).
-
(2009)
Breast Cancer Res. Treat.
, vol.118
, Issue.3
, pp. 523-530
-
-
Pestrin, M.1
Bessi, S.2
Galardi, F.3
-
74
-
-
40449098857
-
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
-
Fehm T, Becker S, Duerr-Stoerzer S et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res. 9(5), R74 (2007).
-
(2007)
Breast Cancer Res.
, vol.9
, Issue.5
-
-
Fehm, T.1
Becker, S.2
Duerr-Stoerzer, S.3
-
75
-
-
3042552362
-
HER-2 gene amplification can be acquired as breast cancer progresses
-
Meng S, Tripathy D, Shete S et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl Acad. Sci. USA 101(25), 9393-9398 (2004).
-
(2004)
Proc. Natl Acad. Sci. USA
, vol.101
, Issue.25
, pp. 9393-9398
-
-
Meng, S.1
Tripathy, D.2
Shete, S.3
-
76
-
-
17144426134
-
Circulating tumor cells predict survival in patients with metastatic prostate cancer
-
Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65(4), 713-718 (2005).
-
(2005)
Urology
, vol.65
, Issue.4
, pp. 713-718
-
-
Moreno, J.G.1
Miller, M.C.2
Gross, S.3
Allard, W.J.4
Gomella, L.G.5
Terstappen, L.W.6
-
77
-
-
37249006715
-
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer
-
DOI 10.1158/1078-0432.CCR-07-1506
-
Danila DC, Heller G, Gignac GA et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 13(23), 7053-7058 (2007). (Pubitemid 350276887)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.23
, pp. 7053-7058
-
-
Danila, D.C.1
Heller, G.2
Gignac, G.A.3
Gonzalez-Espinoza, R.4
Anand, A.5
Tanaka, E.6
Lilja, H.7
Schwartz, L.8
Larson, S.9
Fleisher, M.10
Scher, H.I.11
-
78
-
-
34247502671
-
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer
-
Shaffer DR, Leversha MA, Danila DC et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin. Cancer Res. 13(7), 2023-2029 (2007).
-
(2007)
Clin. Cancer Res.
, vol.13
, Issue.7
, pp. 2023-2029
-
-
Shaffer, D.R.1
Leversha, M.A.2
Danila, D.C.3
-
79
-
-
33749031540
-
Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer
-
Cohen SJ, Alpaugh RK, Gross S et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 6(2), 125-132 (2006).
-
(2006)
Clin. Colorectal Cancer
, vol.6
, Issue.2
, pp. 125-132
-
-
Cohen, S.J.1
Alpaugh, R.K.2
Gross, S.3
-
80
-
-
49249130844
-
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
-
Cohen SJ, Punt CJ, Iannotti N. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(19), 3213-3221 (2008).
-
(2008)
J. Clin. Oncol.
, vol.26
, Issue.19
, pp. 3213-3221
-
-
Cohen, S.J.1
Punt, C.J.2
Iannotti, N.3
-
81
-
-
77952419985
-
Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents
-
Tol J, Koopman M, Miller MC et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann. Oncol. 21(5), 1006-1012 (2010).
-
(2010)
Ann. Oncol.
, vol.21
, Issue.5
, pp. 1006-1012
-
-
Tol, J.1
Koopman, M.2
Miller, M.C.3
-
82
-
-
0141843656
-
The nuclear RNase III Drosha initiates microRNA processing
-
Lee Y, Ahn C, Han J et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425(6956), 415-419 (2003).
-
(2003)
Nature
, vol.425
, Issue.6956
, pp. 415-419
-
-
Lee, Y.1
Ahn, C.2
Han, J.3
-
83
-
-
0035800521
-
A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA
-
Hutvágner G, McLachlan J, Pasquinelli AE, Bálint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 293(5531), 834-838 (2001).
-
(2001)
Science
, vol.293
, Issue.5531
, pp. 834-838
-
-
Hutvágner, G.1
McLachlan, J.2
Pasquinelli, A.E.3
Bálint, E.4
Tuschl, T.5
Zamore, P.D.6
-
84
-
-
77949261485
-
MicroRNAs in cancer - From research to therapy
-
Cho WC. MicroRNAs in cancer - from research to therapy. Biochim. Biophys. Acta 1805(2), 209-217 (2010).
-
(2010)
Biochim. Biophys. Acta
, vol.1805
, Issue.2
, pp. 209-217
-
-
Cho, W.C.1
-
85
-
-
77954386364
-
MicroRNAs: Potential biomarkers for cancer diagnosis prognosis and targets for therapy
-
DOI:10.1016/j.biocel.2009.12.014 Epub ahead of print
-
Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int. J. Biochem Cell Biol. DOI:10.1016/j.biocel.2009. 12.014 (2009) (Epub ahead of print).
-
(2009)
Int. J. Biochem Cell Biol.
-
-
Cho, W.C.1
-
86
-
-
35148886434
-
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
-
Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449(7163), 682-688 (2007).
-
(2007)
Nature
, vol.449
, Issue.7163
, pp. 682-688
-
-
Ma, L.1
Teruya-Feldstein, J.2
Weinberg, R.A.3
-
87
-
-
38049115129
-
Endogenous human microRNAs that suppress breast cancer metastasis
-
Tavazoie SF, Alarcón C, Oskarsson T et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451(7175), 147-152 (2008).
-
(2008)
Nature
, vol.451
, Issue.7175
, pp. 147-152
-
-
Tavazoie, S.F.1
Alarcón, C.2
Oskarsson, T.3
-
88
-
-
40249104566
-
The utility of LNA in microRNA-based cancer diagnostics and therapeutics
-
Stenvang J, Silahtaroglu AN, Lindow M, Elmen J, Kauppinen S. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin. Cancer Biol. 18(2), 89-102 (2008).
-
(2008)
Semin. Cancer Biol.
, vol.18
, Issue.2
, pp. 89-102
-
-
Stenvang, J.1
Silahtaroglu, A.N.2
Lindow, M.3
Elmen, J.4
Kauppinen, S.5
-
89
-
-
41849114566
-
MicroRNAs accurately identify cancer tissue origin
-
Rosenfeld N, Aharonov R, Meiri E et al. MicroRNAs accurately identify cancer tissue origin. Nat. Biotechnol. 26(4), 462-469 (2008).
-
(2008)
Nat. Biotechnol.
, vol.26
, Issue.4
, pp. 462-469
-
-
Rosenfeld, N.1
Aharonov, R.2
Meiri, E.3
-
90
-
-
36048933639
-
Cancer of unknown primary origin: A decade of experience in a community-based hospital
-
Pimiento JM, Teso D, Malkan A, Dudrick SJ, Palesty JA. Cancer of unknown primary origin: a decade of experience in a community-based hospital. Am. J. Surg. 194(6), 833-837 (2007).
-
(2007)
Am. J. Surg.
, vol.194
, Issue.6
, pp. 833-837
-
-
Pimiento, J.M.1
Teso, D.2
Malkan, A.3
Dudrick, S.J.4
Palesty, J.A.5
-
91
-
-
58049213696
-
Dicer, Drosha, and outcomes in patients with ovarian cancer
-
Merritt WM, Lin YG, Han LY et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med. 359(25), 2641-2650 (2008).
-
(2008)
N. Engl. J. Med.
, vol.359
, Issue.25
, pp. 2641-2650
-
-
Merritt, W.M.1
Lin, Y.G.2
Han, L.Y.3
-
92
-
-
20144373433
-
Reduced expression of Dicer associated with poor prognosis in lung cancer patients
-
Karube Y, Tanaka H, Osada H et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 96(2), 111-115 (2005).
-
(2005)
Cancer Sci.
, vol.96
, Issue.2
, pp. 111-115
-
-
Karube, Y.1
Tanaka, H.2
Osada, H.3
-
93
-
-
22244467087
-
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells
-
Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65(14), 6029-6033 (2005).
-
(2005)
Cancer Res.
, vol.65
, Issue.14
, pp. 6029-6033
-
-
Chan, J.A.1
Krichevsky, A.M.2
Kosik, K.S.3
-
94
-
-
34247495591
-
MiR-21-mediated tumor growth
-
Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 26(19), 2799-27803 (2007).
-
(2007)
Oncogene
, vol.26
, Issue.19
, pp. 2799-27803
-
-
Si, M.L.1
Zhu, S.2
Wu, H.3
Lu, Z.4
Wu, F.5
Mo, Y.Y.6
-
95
-
-
34548316982
-
MicroRNA sponges: Competitive inhibitors of small RNAs in mammalian cells
-
Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 4(9), 721-726 (2007).
-
(2007)
Nat. Methods
, vol.4
, Issue.9
, pp. 721-726
-
-
Ebert, M.S.1
Neilson, J.R.2
Sharp, P.A.3
-
96
-
-
66449136951
-
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model
-
Kota J, Chivukula RR, O'Donnell KA et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6), 1005-1017 (2009).
-
(2009)
Cell
, vol.137
, Issue.6
, pp. 1005-1017
-
-
Kota, J.1
Chivukula, R.R.2
O'Donnell, K.A.3
-
97
-
-
73349094741
-
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
-
Laurent-Puig P, Cayre A, Manceau G et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol. 27(35), 5924-5930 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.35
, pp. 5924-5930
-
-
Laurent-Puig, P.1
Cayre, A.2
Manceau, G.3
-
98
-
-
66749094784
-
Lapatinib is active in patients with HER2-amplified breast tumors expressing p95HER2
-
10-14 December, Abstract 708
-
Guix M, Aura CM, Jimenez J et al. Lapatinib is active in patients with HER2-amplified breast tumors expressing p95HER2. San Antonio Breast Cancer Symposium San Antonio, TX, USA 10-14 December 2008 (Abstract 708).
-
(2008)
San Antonio Breast Cancer Symposium San Antonio TX USA
-
-
Guix, M.1
Aura, C.M.2
Jimenez, J.3
|